Logo

454 Licenses Sequencing Techniques from Pyrosequencing

Aug 19, 2003

NEW YORK, Aug. 19 (GenomeWeb News) - CuraGen subsidiary 454 Life Sciences has exclusively licensed sequencing by synthesis and pyrophosphate-based sequencing techniques from Pyrosequencing of Uppsala, Sweden, the companies said today.

 

Under the agreement, 454 of Branford, Conn., will pay Pyrosequencing at least $4.5 million.

After the fifth year, 454 has an option to maintain the exclusivity of the license at a cost of $500,000 to $1 million per year.

 

The license provides 454 with the exclusive worldwide rights for five years to use the technology in whole genome analysis - and in making instruments and kits that use the technology - while Pyrosequencing will retain rights for other applications.

 

 

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.